Shopping Cart
- Remove All
Your shopping cart is currently empty
Dehydroabiethylamine (NSC-2955) is an inducer of hepatic CYP2B activity. Dehydroabiethylamine inhibits pyruvate dehydrogenase kinases (PDKs) and intracellular cholesterol transport with anti-tumor activity.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 g | $33 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $29 | In Stock |
| Description | Dehydroabiethylamine (NSC-2955) is an inducer of hepatic CYP2B activity. Dehydroabiethylamine inhibits pyruvate dehydrogenase kinases (PDKs) and intracellular cholesterol transport with anti-tumor activity. |
| Synonyms | NSC-2955, NSC2955, NSC 2955, Leelamine free base, Leelamine, Dehydroabietylamine |
| Molecular Weight | 285.47 |
| Formula | C20H31N |
| Cas No. | 1446-61-3 |
| Smiles | [H][C@@]12CCc3cc(ccc3[C@@]1(C)CCC[C@@]2(C)CN)C(C)C |
| Relative Density. | 0.963 g/cm3 |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 25 mg/mL (87.57 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (7.01 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.